4D Molecular Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Portfolio Pulse from Benzinga Insights
Analyst perspectives on 4D Molecular Therapeutics (NASDAQ:FDMT) show a mix of bullish and bearish views with 5 recent ratings. The average 12-month price target is $49.4, reflecting a 31.73% increase from the previous $37.50. Analysts from HC Wainwright & Co., Goldman Sachs, BMO Capital, and RBC Capital have provided updates, with price targets ranging from $25.00 to $81.00. 4D Molecular Therapeutics, a clinical-stage gene therapy company, has shown significant revenue growth and solid financial performance, with a notable market capitalization and positive indicators such as net margin, ROE, and ROA.
March 01, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics has received mixed analyst ratings but an overall positive adjustment in price targets, indicating a bullish outlook from the financial community. The company's strong financial performance and significant revenue growth are likely to positively influence investor sentiment.
The increase in the average price target and positive financial indicators such as revenue growth, net margin, ROE, and ROA suggest a bullish sentiment among analysts. This, combined with the company's advancements in gene therapy, positions FDMT favorably in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100